Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

478.13
-14.2500-2.89%
Post-market: 478.130.00000.00%16:20 EDT
Volume:1.59M
Turnover:765.86M
Market Cap:121.31B
PE:31.21
High:489.97
Open:489.97
Low:476.57
Close:492.38
52wk High:519.68
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.90
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.32
EPS(LYR):15.32
ROE:22.54%
ROA:12.16%
PB:6.50
PE(LYR):31.21

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG)

TIPRANKS
·
Feb 15

Vertex Pharmaceuticals Inc. Stock Rallies 5.7%, Outperforms Peers

Dow Jones
·
Feb 14

Vertex Pharmaceuticals Up Over 6%, On Track for Highest Close Since May 2025 -- Data Talk

Dow Jones
·
Feb 14

Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says

MT Newswires Live
·
Feb 14

Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says

MT Newswires Live
·
Feb 14

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-02-13

Reuters
·
Feb 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Maravai Lifesciences Holdings (MRVI) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals (VRTX) Receives a Buy from Evercore ISI

TIPRANKS
·
Feb 13

Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report

Stock Track
·
Feb 13

Morgan Stanley Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Feb 13

Scotiabank Adjusts Vertex Pharmaceuticals PT to $558 From $495, Maintains Sector Outperform Rating

MT Newswires Live
·
Feb 13

Vertex Pharmaceuticals EVP Edward Morrow Atkinson III Reports Sale of Common Shares

Reuters
·
Feb 13

Kristen Ambrose, SVP & Chief Accounting Officer, Reports Disposal of Vertex Pharmaceuticals Common Shares

Reuters
·
Feb 13

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

Dow Jones
·
Feb 13

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Reuters
·
Feb 13

Vertex Pharmaceuticals Q4 Adj. EPS $5.03 Misses $5.07 Estimate, Sales $3.190B Beat $3.176B Estimate

Benzinga
·
Feb 13

Vertex posts FY2025 GAAP operating income of USD 4.17 billion

Reuters
·
Feb 13

Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Revenue $3.19B, vs. FactSet Est of $3.18B

MT Newswires Live
·
Feb 13